Zulvac 1 Ovis

RSS

Withdrawn

This medicine's authorisation has been withdrawn

inactivated bluetongue virus, serotype-1
MedicineVeterinaryWithdrawn

Slovenian is available via eTranslation, the European Commission's machine translation service.

Translate to Slovenian | Important information about machine translation

  • Application under evaluation
  • CVMP opinion
  • European Commission decision

Overview

The marketing authorisation for Zulvac 1 Ovis has been withdrawn at the request of the marketing-authorisation holder.

български (BG) (387.71 KB - PDF)

Prikaži

español (ES) (324.29 KB - PDF)

Prikaži

čeština (CS) (367.61 KB - PDF)

Prikaži

dansk (DA) (311.6 KB - PDF)

Prikaži

Deutsch (DE) (339.3 KB - PDF)

Prikaži

ελληνικά (EL) (425.96 KB - PDF)

Prikaži

français (FR) (340.13 KB - PDF)

Prikaži

italiano (IT) (335.8 KB - PDF)

Prikaži

latviešu (LV) (411.71 KB - PDF)

Prikaži

lietuvių (LT) (350.56 KB - PDF)

Prikaži

magyar (HU) (383.87 KB - PDF)

Prikaži

Malti (MT) (373.83 KB - PDF)

Prikaži

Nederlands (NL) (320.6 KB - PDF)

Prikaži

polski (PL) (381.01 KB - PDF)

Prikaži

português (PT) (329.18 KB - PDF)

Prikaži

română (RO) (327.6 KB - PDF)

Prikaži

slovenčina (SK) (357.21 KB - PDF)

Prikaži

slovenščina (SL) (375.83 KB - PDF)

Prikaži

suomi (FI) (335.83 KB - PDF)

Prikaži

svenska (SV) (303.24 KB - PDF)

Prikaži

Product information

български (BG) (747.04 KB - PDF)

Prikaži

español (ES) (415.86 KB - PDF)

Prikaži

čeština (CS) (625.49 KB - PDF)

Prikaži

dansk (DA) (420.56 KB - PDF)

Prikaži

Deutsch (DE) (442.48 KB - PDF)

Prikaži

eesti (ET) (426.62 KB - PDF)

Prikaži

ελληνικά (EL) (744.06 KB - PDF)

Prikaži

français (FR) (441.63 KB - PDF)

Prikaži

hrvatski (HR) (487.06 KB - PDF)

Prikaži

italiano (IT) (439.98 KB - PDF)

Prikaži

latviešu (LV) (612.09 KB - PDF)

Prikaži

lietuvių (LT) (492.04 KB - PDF)

Prikaži

magyar (HU) (645.11 KB - PDF)

Prikaži

Malti (MT) (643.64 KB - PDF)

Prikaži

Nederlands (NL) (428.46 KB - PDF)

Prikaži

polski (PL) (637.5 KB - PDF)

Prikaži

português (PT) (424.02 KB - PDF)

Prikaži

română (RO) (523 KB - PDF)

Prikaži

slovenčina (SK) (629.98 KB - PDF)

Prikaži

slovenščina (SL) (619.27 KB - PDF)

Prikaži

suomi (FI) (412.23 KB - PDF)

Prikaži

svenska (SV) (434.1 KB - PDF)

Prikaži

Íslenska (IS) (431.83 KB - PDF)

Prikaži

norsk (NO) (426.93 KB - PDF)

Prikaži
Latest procedure affecting product information:IB/00017
21/06/2019

български (BG) (853.9 KB - PDF)

Prikaži

español (ES) (837.98 KB - PDF)

Prikaži

čeština (CS) (862.38 KB - PDF)

Prikaži

dansk (DA) (806.02 KB - PDF)

Prikaži

Deutsch (DE) (827.27 KB - PDF)

Prikaži

eesti (ET) (805.45 KB - PDF)

Prikaži

ελληνικά (EL) (877.4 KB - PDF)

Prikaži

français (FR) (824.01 KB - PDF)

Prikaži

italiano (IT) (801.5 KB - PDF)

Prikaži

latviešu (LV) (843.42 KB - PDF)

Prikaži

lietuvių (LT) (1.38 MB - PDF)

Prikaži

magyar (HU) (853.89 KB - PDF)

Prikaži

Malti (MT) (847.1 KB - PDF)

Prikaži

Nederlands (NL) (824.2 KB - PDF)

Prikaži

polski (PL) (862.36 KB - PDF)

Prikaži

português (PT) (837.86 KB - PDF)

Prikaži

română (RO) (1.38 MB - PDF)

Prikaži

slovenčina (SK) (839.69 KB - PDF)

Prikaži

slovenščina (SL) (858.77 KB - PDF)

Prikaži

suomi (FI) (824.89 KB - PDF)

Prikaži

svenska (SV) (805.81 KB - PDF)

Prikaži

Íslenska (IS) (806.86 KB - PDF)

Prikaži

norsk (NO) (804.7 KB - PDF)

Prikaži

Product details

Name of medicine
Zulvac 1 Ovis
Active substance
inactivated bluetongue virus, serotype-1
International non-proprietary name (INN) or common name
inactivated bluetongue virus, serotype-1
Species
Sheep
Anatomical therapeutic chemical veterinary (ATCvet) code
QI04AA02

Pharmacotherapeutic group

Immunologicals

Therapeutic indication

Active immunisation of sheep from 1.5 months of age for the prevention of viraemia caused by bluetongue virus, serotypes-1.

Onset of immunity: 21 days after completion of the primary vaccination scheme.

Duration of immunity: 12 months.

Authorisation details

EMA product number
EMEA/V/C/002335

Accelerated assessment

This medicine had an accelerated assessment. This means that it is a medicine of major interest for public health, so its timeframe for review was 150 evaluation days rather than 210. For more information, see Accelerated assessment.

Marketing authorisation holder
Zoetis Belgium SA

Rue Laid Burniat 1
1348 Louvain-la-Neuve
Belgium

Marketing authorisation issued
05/08/2011
Revision
6

Assessment history

This page was last updated on

Share this page